Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Income from Continuing Operations (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Income from Continuing Operations for 15 consecutive years, with 27525000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 367.86% to 27525000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 78361000.0 through Dec 2025, up 523.07% year-over-year, with the annual reading at 78337000.0 for FY2025, 522.94% up from the prior year.
  • Income from Continuing Operations hit 27525000.0 in Q4 2025 for Ani Pharmaceuticals, up from 26600000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 27525000.0 in Q4 2025 to a low of 24166000.0 in Q3 2024.
  • Historically, Income from Continuing Operations has averaged 590600.0 across 5 years, with a median of 1088500.0 in 2021.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 18370.0% in 2022 and later skyrocketed 1135.21% in 2024.
  • Year by year, Income from Continuing Operations stood at 24098000.0 in 2021, then skyrocketed by 82.24% to 4280000.0 in 2022, then surged by 126.99% to 1155000.0 in 2023, then plummeted by 989.7% to 10276000.0 in 2024, then soared by 367.86% to 27525000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ANIP at 27525000.0 in Q4 2025, 26600000.0 in Q3 2025, and 8549000.0 in Q2 2025.